(CNO) CNO Financial - Ratings and Ratios
Medicare, Medigap, Annuity, Universal, Term
CNO EPS (Earnings per Share)
CNO Revenue
Description: CNO CNO Financial
CNO Financial Group Inc (NYSE:CNO) is a leading provider of health insurance, annuity, and life insurance products to middle-income Americans, particularly pre-retirees and retirees. The company operates through its subsidiaries, offering a range of products, including Medicare supplement, long-term care insurance, life insurance, and annuities, primarily through phone, online, and face-to-face interactions with agents.
The companys product portfolio is diverse, with a focus on fixed indexed annuities, fixed interest annuities, and supplemental health products, such as specified disease and accident insurance. CNO Financial Group also offers universal life and other interest-sensitive life products, as well as traditional life policies, including whole life, graded benefit life, and term life products. The companys brands, including Bankers Life, Washington National, and Colonial Penn, are well-established in the market.
From a financial perspective, CNO Financial Group has a market capitalization of approximately $3.67 billion, with a price-to-earnings ratio of 12.93 and a forward P/E of 9.71. The companys return on equity (RoE) is around 10.97%, indicating a relatively stable and profitable business. To further evaluate the companys performance, key performance indicators (KPIs) such as the insurance companys loss ratio, expense ratio, and combined ratio can be analyzed. A loss ratio below 70% and a combined ratio below 100% would indicate a profitable underwriting business. Additionally, metrics such as the companys asset yield, investment income, and capital adequacy can provide insights into its financial health and stability.
To assess CNO Financial Groups future prospects, it is essential to examine industry trends, competitive landscape, and the companys strategic initiatives. The life and health insurance industry is subject to various factors, including regulatory changes, demographic shifts, and economic fluctuations. CNO Financial Groups ability to adapt to these changes and execute its business strategy will be crucial to its long-term success. Key drivers of growth, such as the increasing demand for retirement and health insurance products, can be analyzed to estimate the companys potential for expansion.
CNO Stock Overview
| Market Cap in USD | 3,538m |
| Sector | Financial Services |
| Industry | Insurance - Life |
| GiC Sub-Industry | Life & Health Insurance |
| IPO / Inception | 1987-01-01 |
CNO Stock Ratings
| Growth Rating | 73.6 |
| Fundamental | 61.2% |
| Dividend Rating | 63.6 |
| Rel. Strength | -3.89 |
| Analysts | 2.83 of 5 |
| Fair Price Momentum | 39.03 USD |
| Fair Price DCF | 122.87 USD |
CNO Dividends
| Dividend Yield 12m | 1.74% |
| Yield on Cost 5y | 4.38% |
| Annual Growth 5y | 6.03% |
| Payout Consistency | 100.0% |
| Payout Ratio | 15.9% |
CNO Growth Ratios
| Growth Correlation 3m | -62.8% |
| Growth Correlation 12m | 41.7% |
| Growth Correlation 5y | 78.8% |
| CAGR 5y | 20.06% |
| CAGR/Max DD 5y | 0.53 |
| Sharpe Ratio 12m | 0.90 |
| Alpha | 0.62 |
| Beta | 0.854 |
| Volatility | 30.01% |
| Current Volume | 545.4k |
| Average Volume 20d | 720.7k |
| Stop Loss | 35.9 (-3.1%) |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (280.9m TTM) > 0 and > 6% of Revenue (6% = 261.7m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA 0.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -53.46% (prev 19.71%; Δ -73.17pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 704.4m > Net Income 280.9m (YES >=105%, WARN >=100%) |
| Net Debt (3.01b) to EBITDA (840.3m) ratio: 3.58 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (103.1m) change vs 12m ago -5.66% (target <= -2.0% for YES) |
| Gross Margin 37.45% (prev 76.08%; Δ -38.63pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 11.85% (prev 12.09%; Δ -0.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.16 (EBITDA TTM 840.3m / Interest Expense TTM 251.1m) >= 6 (WARN >= 3) |
Altman Z'' -0.07
| (A) -0.06 = (Total Current Assets 1.05b - Total Current Liabilities 3.38b) / Total Assets 37.33b |
| (B) 0.06 = Retained Earnings (Balance) 2.33b / Total Assets 37.33b |
| (C) 0.01 = EBIT TTM 543.4m / Avg Total Assets 36.81b |
| (D) 0.03 = Book Value of Equity 1.08b / Total Liabilities 34.81b |
| Total Rating: -0.07 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.22
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield 7.58% = 3.79 |
| 3. FCF Margin 16.15% = 4.04 |
| 4. Debt/Equity 2.60 = -0.16 |
| 5. Debt/Ebitda 7.82 = -2.50 |
| 6. ROIC - WACC 2.48% = 3.10 |
| 7. RoE 10.97% = 0.91 |
| 8. Rev. Trend 63.03% = 3.15 |
| 9. Rev. CAGR 7.72% = 0.96 |
| 10. EPS Trend data missing |
| 11. EPS CAGR -0.56% = -0.07 |
As of August 13, 2025, the stock is trading at USD 37.03 with a total of 545,421 shares traded.
Over the past week, the price has changed by +3.32%, over one month by +1.93%, over three months by -3.71% and over the past year by +19.87%.
Neither. Based on ValueRay´s Fundamental Analyses, CNO Financial is currently (August 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 61.22 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CNO is around 39.03 USD . This means that CNO is currently overvalued and has a potential downside of 5.4%.
CNO Financial has received a consensus analysts rating of 2.83. Therefor, it is recommend to hold CNO.
- Strong Buy: 0
- Buy: 1
- Hold: 4
- Sell: 0
- Strong Sell: 1
According to our own proprietary Forecast Model, CNO CNO Financial will be worth about 41.6 in August 2026. The stock is currently trading at 37.03. This means that the stock has a potential upside of +12.31%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 42.4 | 14.5% |
| Analysts Target Price | 44.2 | 19.4% |
| ValueRay Target Price | 41.6 | 12.3% |
CNO Fundamental Data Overview
CCE Cash And Equivalents = 816.0m USD (last quarter)
P/E Trailing = 13.1769
P/E Forward = 9.7087
P/S = 0.8073
P/B = 1.4025
P/EG = 1.58
Beta = 0.915
Revenue TTM = 4.36b USD
EBIT TTM = 543.4m USD
EBITDA TTM = 840.3m USD
Long Term Debt = 4.13b USD (from longTermDebt, last quarter)
Short Term Debt = 2.44b USD (from shortTermDebt, last quarter)
Debt = 6.57b USD (Calculated: Short Term 2.44b + Long Term 4.13b)
Net Debt = 3.01b USD (from netDebt column, last quarter)
Enterprise Value = 9.29b USD (3.54b + Debt 6.57b - CCE 816.0m)
Interest Coverage Ratio = 2.16 (Ebit TTM 543.4m / Interest Expense TTM 251.1m)
FCF Yield = 7.58% (FCF TTM 704.4m / Enterprise Value 9.29b)
FCF Margin = 16.15% (FCF TTM 704.4m / Revenue TTM 4.36b)
Net Margin = 6.44% (Net Income TTM 280.9m / Revenue TTM 4.36b)
Gross Margin = 37.45% ((Revenue TTM 4.36b - Cost of Revenue TTM 2.73b) / Revenue TTM)
Tobins Q-Ratio = 8.59 (Enterprise Value 9.29b / Book Value Of Equity 1.08b)
Interest Expense / Debt = 0.90% (Interest Expense 59.1m / Debt 6.57b)
Taxrate = 22.05% (from yearly Income Tax Expense: 114.3m / 518.3m)
NOPAT = 423.6m (EBIT 543.4m * (1 - 22.05%))
Current Ratio = 0.31 (Total Current Assets 1.05b / Total Current Liabilities 3.38b)
Debt / Equity = 2.60 (Debt 6.57b / last Quarter total Stockholder Equity 2.52b)
Debt / EBITDA = 7.82 (Net Debt 3.01b / EBITDA 840.3m)
Debt / FCF = 9.33 (Debt 6.57b / FCF TTM 704.4m)
Total Stockholder Equity = 2.56b (last 4 quarters mean)
RoA = 0.75% (Net Income 280.9m, Total Assets 37.33b )
RoE = 10.97% (Net Income TTM 280.9m / Total Stockholder Equity 2.56b)
RoCE = 8.12% (Ebit 543.4m / (Equity 2.56b + L.T.Debt 4.13b))
RoIC = 6.14% (NOPAT 423.6m / Invested Capital 6.90b)
WACC = 3.66% (E(3.54b)/V(10.11b) * Re(9.16%)) + (D(6.57b)/V(10.11b) * Rd(0.90%) * (1-Tc(0.22)))
Shares Correlation 5-Years: -100.0 | Cagr: -3.79%
Discount Rate = 9.16% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 75.07% ; FCFE base≈648.6m ; Y1≈694.5m ; Y5≈843.0m
Fair Price DCF = 122.9 (DCF Value 11.91b / Shares Outstanding 96.9m; 5y FCF grow 7.93% → 2.90% )
Revenue Correlation: 63.03 | Revenue CAGR: 7.72%
Revenue Growth Correlation: -61.07%
EPS Correlation: N/A | EPS CAGR: -0.56%
EPS Growth Correlation: 24.72%
Additional Sources for CNO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle